Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin

E-ISSN： 1875-5992|15|3|298-306

ISSN： 1871-5206

Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.15, Iss.3, 2015-03, pp. : 298-306

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Carfilzomib: a novel second-generation proteasome inhibitor

By Khan Meaghan L Stewart A Keith

Future Oncology, Vol. 7, Iss. 5, 2011-05 ,pp. : 607-612

Future Medicine

Access to resources Recommend Favorite

Second Generation Taxanes: from the Natural Framework to the Challenge of Drug Resistance

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 3, Iss. 2, 2003-01 ,pp. : 133-138

Bentham Science Publishers

Access to resources Recommend Favorite

RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ERnegative breast cancer models

International Journal of Oncology, Vol. 41, Iss. 5, 2012-01 ,pp. : 1723-1732

Spandidos Publications

Access to resources Recommend Favorite

Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN

Oncology Letters, Vol. 4, Iss. 6, 2012-01 ,pp. : 1305-1308

Spandidos Publications

Access to resources Recommend Favorite

MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma

By Amato Robert J. Stephenson Joe Hotte Sebastien Nemunaitis John Bélanger Karl Reid Gregory Martell Robert E.

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 415-421

Informa Healthcare

Access to resources Recommend Favorite